Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1972 Jun 10;106(11):1169–1174.

Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease

André Barbeau, Harold Mars, Mihai I Botez, Marie Joubert
PMCID: PMC1940581  PMID: 5034697

Abstract

The authors report their experience, over a 26-month period, in the management of 60 parkinsonian patients with the combination of levodopa and an inhibitor of peripheral dopa-decarboxylase, Ro 4-4602. This approach to Parkinson's disease is useful, safe, and at least as effective as levodopa alone. To date there have been no recognizable toxic effects attributable to Ro 4-4602. This agent appears to prolong the duration of action of levodopa, smoothing out its therapeutic effects. The percentage of patients obtaining a very good and excellent response is slightly increased. There is a possible diminution in the late-occurring bradykinetic and hypotonic freezing episodes. Nausea and cardiac arrhythmias are lessened, as are the incidence and severity of hypotension. Abnormal involuntary movements remain the limiting adverse side effect.

Full text

PDF
1169

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau A. Dopamine and disease. Can Med Assoc J. 1970 Oct 17;103(8):824–832. [PMC free article] [PubMed] [Google Scholar]
  2. Barbeau A., Friesen H. Treatment of Wilson's disease with L-dopa after failure with penicillamine. Lancet. 1970 May 30;1(7657):1180–1181. doi: 10.1016/s0140-6736(70)91259-6. [DOI] [PubMed] [Google Scholar]
  3. Barbeau A., Gillo-Joffroy L., Boucher R., Nowaczynski W., Genest J. Renin-aldosterone system in Parkinson's disease. Science. 1969 Jul 18;165(3890):291–292. doi: 10.1126/science.165.3890.291. [DOI] [PubMed] [Google Scholar]
  4. Barbeau A., Gillo-Joffroy L., Mars H. Treatment of Parkinson's disease with levodopa and Ro 4-4602. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):353–359. doi: 10.1002/cpt1971122part2353. [DOI] [PubMed] [Google Scholar]
  5. Barbeau A. L-dopa and juvenile Huntington's disease. Lancet. 1969 Nov 15;2(7629):1066–1066. doi: 10.1016/s0140-6736(69)90662-x. [DOI] [PubMed] [Google Scholar]
  6. Barbeau A. Long-term side-effects of levodopa. Lancet. 1971 Feb 20;1(7695):395–395. doi: 10.1016/s0140-6736(71)92226-4. [DOI] [PubMed] [Google Scholar]
  7. Barbeau A. Parkinson's disease. Recent advances in treatment. N Y State J Med. 1970 Oct 1;70(19):2437–2443. [PubMed] [Google Scholar]
  8. Bartholini G., Blum J. E., Pletscher A. Dopa-induced locomotor stimulation after inhibition of extracerebral decarboxylase. J Pharm Pharmacol. 1969 May;21(5):297–301. doi: 10.1111/j.2042-7158.1969.tb08253.x. [DOI] [PubMed] [Google Scholar]
  9. Bartholini G., Burkard W. P., Pletscher A. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature. 1967 Aug 19;215(5103):852–853. doi: 10.1038/215852b0. [DOI] [PubMed] [Google Scholar]
  10. Bartholini G., Da Prada M., Pletscher A. Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J Pharm Pharmacol. 1968 Mar;20(3):228–229. doi: 10.1111/j.2042-7158.1968.tb09726.x. [DOI] [PubMed] [Google Scholar]
  11. Bartholini G., Pletscher A. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase. J Pharmacol Exp Ther. 1968 May;161(1):14–20. [PubMed] [Google Scholar]
  12. Birkmayer W. Experimentelle Ergebnisse über die Kombinationsbehandlung des Parkinson-Syndroms mit L-DOPA und einem Decarboxylasehemmer (Ro 4-4602) Wien Klin Wochenschr. 1969 Sep 26;81(39):677–679. [PubMed] [Google Scholar]
  13. Birkmayer W., Mentasti M. Weitere experimentelle Untersuchungen über den Catecholaminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson- und Chorea-Syndrom) Arch Psychiatr Nervenkr (1970) 1967 Aug 8;210(1):29–35. doi: 10.1007/BF01217333. [DOI] [PubMed] [Google Scholar]
  14. Burn J. H. Hypotension caused by L-dopa. Br Med J. 1970 Mar 7;1(5696):629–629. doi: 10.1136/bmj.1.5696.629-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chase T. N. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism. Neurology. 1970 Dec;20(12):36–40. [PubMed] [Google Scholar]
  16. Cotzias G. C. Metabolic modification of some neurologic disorders. JAMA. 1969 Nov 17;210(7):1255–1262. [PubMed] [Google Scholar]
  17. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  18. Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
  19. DERY J. P., de GROOT J., LAURIN C., BARBEAU A. [Antiparkinsonian agents. 1. New method of objective evaluation of rigidity and tremor in Parkinson's disease]. Union Med Can. 1962 Aug;91:842–847. [PubMed] [Google Scholar]
  20. Ganten D., Minnich J. L., Granger P., Hayduk K., Brecht H. M., Barbeau A., Boucher R., Genest J. Angiotensin-forming enzyme in brain tissue. Science. 1971 Jul 2;173(3991):64–65. doi: 10.1126/science.173.3991.64. [DOI] [PubMed] [Google Scholar]
  21. Gauthier G., de Ajuriaguerra J., Simona B., Constantinidis J., Eisenring J. J., Krassoievitch M., Yanniotis G., Tissot R. Thérapeutique du syndrome parkinsonien par la L-Dopa associée à des inhibiteurs de la décarboxylase. I. Rev Neurol (Paris) 1970 Nov;123(5):297–319. [PubMed] [Google Scholar]
  22. Henning M., Rubenson A. Evidence for a centrally mediated hypotensive effect of L-dopa in the rat. J Pharm Pharmacol. 1970 Mar;22(3):241–243. doi: 10.1111/j.2042-7158.1970.tb08510.x. [DOI] [PubMed] [Google Scholar]
  23. Joubert M., Barbeau A. Méthode de mesure de l'akinésie. Union Med Can. 1966 May;95(5):531–535. [PubMed] [Google Scholar]
  24. Klawans H. C., Paulson G. W., Barbeau A. Predictive test for Huntington's chorea. Lancet. 1970 Dec 5;2(7684):1185–1186. doi: 10.1016/s0140-6736(70)90367-3. [DOI] [PubMed] [Google Scholar]
  25. Krayenbuhl H., Siegfried J. Traitement de la maladie de Parkinson: L-DOPA ou stéréotaxie? Neurochirurgie. 1970 Jan-Feb;16(1):71–76. [PubMed] [Google Scholar]
  26. Lee J. E., Sweet R. D., McDowell F. H. Treatment of parkinsonism with levodopa. Follow-up after 2 years of treatment. Ann Intern Med. 1971 Nov;75(5):703–708. doi: 10.7326/0003-4819-75-5-703. [DOI] [PubMed] [Google Scholar]
  27. Lotti V. J., Porter C. C. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors. J Pharmacol Exp Ther. 1970 Apr;172(2):406–415. [PubMed] [Google Scholar]
  28. McDowell F., Lee J. E., Swift T., Sweet R. D., Ogsbury J. S., Kessler J. T. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa). Ann Intern Med. 1970 Jan;72(1):29–35. doi: 10.7326/0003-4819-72-1-29. [DOI] [PubMed] [Google Scholar]
  29. Michelakis A. M., Robertson D. Plasma renin activity and levodopa in Parkinson's disease. JAMA. 1970 Jul 6;213(1):83–85. [PubMed] [Google Scholar]
  30. Siegfried J. Deux ans d'expérience avec la L-DOPA associée à un inhibiteur de la décarboxylase. Rev Neurol (Paris) 1970 Apr;122(4):243–248. [PubMed] [Google Scholar]
  31. Siegfried J., Klaiber R., Perret E., Ziegler W. H. Behandlung des Morbus Parkinson mit L-Dopa in Kombination mit einem Decarboxylasehemmer. Dtsch Med Wochenschr. 1969 Dec 26;94(52):2678–2681. doi: 10.1055/s-0028-1110503. [DOI] [PubMed] [Google Scholar]
  32. Tissot R., Bartholini G., Pletscher A. Drug-induced changes of extracerebral dopa metabolism in man. Arch Neurol. 1969 Feb;20(2):187–190. doi: 10.1001/archneur.1969.00480080087010. [DOI] [PubMed] [Google Scholar]
  33. Tissot R., Gaillard J. M., Guggisberg M., Gauthier G., de Ajuriaguerra J. Thérapeutique du syndrome de Parkinson par la L-Dopa "per os" associée à un inhibiteur de la décarbosylase (Ro IV 46.02) Presse Med. 1969 Apr 5;77(17):619–622. [PubMed] [Google Scholar]
  34. Watanabe A. M., Chase T. N., Cardon P. V. Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther. 1970 Sep-Oct;11(5):740–746. doi: 10.1002/cpt1970115740. [DOI] [PubMed] [Google Scholar]
  35. Watanabe A. M., Parks L. C., Kopin I. J. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors. J Clin Invest. 1971 Jun;50(6):1322–1328. doi: 10.1172/JCI106611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Yahr M. D., Duvoisin R. C., Schear M. J., Barrett R. E., Hoehn M. M. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343–354. doi: 10.1001/archneur.1969.00480160015001. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES